Literature DB >> 15801823

Structure-activity relationships of pregabalin and analogues that target the alpha(2)-delta protein.

Thomas R Belliotti1, Thomas Capiris, I Victor Ekhato, Jack J Kinsora, Mark J Field, Thomas G Heffner, Leonard T Meltzer, Jacob B Schwarz, Charles P Taylor, Andrew J Thorpe, Mark G Vartanian, Lawrence D Wise, Ti Zhi-Su, Mark L Weber, David J Wustrow.   

Abstract

Pregabalin exhibits robust activity in preclinical assays indicative of potential antiepileptic, anxiolytic, and antihyperalgesic clinical efficacy. It binds with high affinity to the alpha(2)-delta subunit of voltage-gated calcium channels and is a substrate of the system L neutral amino acid transporter. A series of pregabalin analogues were prepared and evaluated for their alpha(2)-delta binding affinity as demonstrated by their ability to inhibit binding of [(3)H]gabapentin to pig brain membranes and for their potency to inhibit the uptake of [(3)H]leucine into CHO cells, a measure of their ability to compete with the endogenous substrate at the system L transporter. Compounds were also assessed in vivo for their ability to promote anxiolytic, analgesic, and anticonvulsant actions. These studies suggest that distinct structure activity relationships exist for alpha(2)-delta binding and system L transport inhibition. However, both interactions appear to play an important role in the in vivo profile of these compounds.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15801823     DOI: 10.1021/jm049762l

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  38 in total

1.  New Horizons in the development of antiepileptic drugs: Innovative strategies.

Authors:  Wolfgang Löscher; Dieter Schmidt
Journal:  Epilepsy Res       Date:  2006-06       Impact factor: 3.045

Review 2.  Molecular targets versus models for new antiepileptic drug discovery.

Authors:  Michael A Rogawski
Journal:  Epilepsy Res       Date:  2006-01       Impact factor: 3.045

Review 3.  Pregabalin: a review of its use in fibromyalgia.

Authors:  Katherine A Lyseng-Williamson; M Asif A Siddiqui
Journal:  Drugs       Date:  2008       Impact factor: 9.546

4.  Optimised protocol design for the screening of analgesic compounds in neuropathic pain.

Authors:  A Taneja; J Nyberg; M Danhof; O Della Pasqua
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-11-30       Impact factor: 2.745

Review 5.  Pregabalin: a review of its use in adults with generalized anxiety disorder.

Authors:  James E Frampton
Journal:  CNS Drugs       Date:  2014-09       Impact factor: 5.749

6.  Effects of antiepileptic drugs on glutamate release from rat and human neocortical synaptosomes.

Authors:  M Kammerer; B Brawek; T M Freiman; R Jackisch; Thomas J Feuerstein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-03-30       Impact factor: 3.000

Review 7.  Molecular targets for antiepileptic drug development.

Authors:  Brian S Meldrum; Michael A Rogawski
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

Review 8.  A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin.

Authors:  Howard N Bockbrader; David Wesche; Raymond Miller; Sunny Chapel; Nancy Janiczek; Paula Burger
Journal:  Clin Pharmacokinet       Date:  2010-10       Impact factor: 6.447

9.  Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin.

Authors:  Jan Hendrich; Alexandra Tran Van Minh; Fay Heblich; Manuela Nieto-Rostro; Katrin Watschinger; Jörg Striessnig; Jack Wratten; Anthony Davies; Annette C Dolphin
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-25       Impact factor: 11.205

Review 10.  Pregabalin: in the treatment of postherpetic neuralgia.

Authors:  Kate McKeage; Susan J Keam
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.